RBC Capital analyst Ben Hendrix keeps an Outperform rating and $596 price target on UnitedHealth after its Q4 results and affirmed FY24 guidance. The company is well positioned in Medicare Advantage this year, with superior margin visibility versus peers who may be more heavily indexed to supplemental benefits, the analyst tells investors in a research note. Utilization concerns drove the pullback in shares on Friday after earnings, but UnitedHealth looks to be “priced well for 2024”, RBC added.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on UNH:
- UnitedHealth says experienced one of best selling years ever
- Unusually active option classes on open January 12th
- Options Volatility and Implied Earnings Moves Today, January 12, 2024
- UnitedHealth (NYSE:UNH) Drops on Q4 Results
- UnitedHealth backs FY24 adjusted EPS view $27.50-$28.00, consensus $27.89
